You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. sHLA Protein Chip

    SBC: GENOMICS USA, INC.            Topic: NIAID

    Abstract: “sHLA Protein Chip” The class I [A, B, C] and class II HLA proteins [DRB1, DQ, DP] comprise the heart of the inducible human immune system. For organ, marrow and stem cell transplantation, the development of serum-born antibodies against one or more of those many HLA proteins comprises the best and earliest test for transplant rejection. Because of the enormous medical importance of ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Development of Taenia Solium Specific Aptamers for Diagnostic Assays

    SBC: LYNNTECH INC.            Topic: ODCDC

    The parasitic tapeworm Taenia solium causes two diseasestaeniasisadult worm in the intestineand cysticercosistissue infection by the cystwhich can lead to seizuresThe Tsolium life cycle involves both humans and pigshowever humans are the only definitive host for the adult Tsolium tapewormDiagnosing people infected with the adult worm is a critical step toward eliminating Tsolium althogetherHowever ...

    SBIR Phase I 2018 Department of Health and Human ServicesCenters for Disease Control and Prevention
  3. Topic 346: Targeted Radionuclide Therapy of Neuroendocrine Tumors Using 212Pb-octreotate Analogs

    SBC: RADIOMEDIX, INC.            Topic: NCI

    A peptide receptor radionuclide therapy (PRRT) using [177Lu]/[90Y]-labeled somatostatin analogs has been proven to induce objective response in 30-45% of patients with advanced/progressive neuroendocrine tumors (NETs). The complete response to beta-emitter PRRT is rare. This is due to the fact that NETs are diagnosed at late stage of disease; the NETs patients with remissions could develop resista ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Topic 379: Extensible and Scalable Platform for Data Integration from Wearable Sensors to Generate Novel Analytics for Cancer Patients

    SBC: Litmus Health, Inc.            Topic: NCI

    The longterm objective of the Litmus Health platform is to allow researchers and clinicians to use data on cancer patients from wearables/sensors and smartphones. Collecting real-time, high-quality data from patients will transform care and clinical trials. Automating data collection, storage, analysis, and interpretation of data will result in better measurement of signs and symptoms and improved ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Topic 372: Highly multiplexed selection of aptamers to hundreds of canine immunotherapy targets

    SBC: BASE PAIR BIOTECHNOLOGIES INC            Topic: NCI

    The preclinical development of cancer therapeutics, including the recent trend and focus on cancer immunotherapies, is evolving from the traditional use of mouse models to the use of other animal models including canine, rat, and minipig. Each of these non-mouse models carries its own advantages and abilities to increase the clinical relevance of the model as compared to mouse models. Yet, the wid ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  6. In situ assay for RNA decapping in tumors

    SBC: VIVID TECHNOLOGIES INC            Topic: 102

    In situ assay for RNA decapping in tumors Abstract This project aims to introduce a new histotechnology to assess tumor cell stress and cell death propensitywhich can be useful in evaluating cancer response to therapyThe adaptive response of tumor cells to stress and their survival in hostile environments are signaled by the levels of mRNA decayIncreased decay dumps important mRNAs and marks cells ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Polyketide chiral building blocks and biocatalysts

    SBC: Coala Biosciences            Topic: 300

    PROJECT SUMMARY As with most synthetic chemistsCoALA Biosciences is inspired by naturally occurring polyketide assembly lineswhich synthesize diverse medicines through reactions that generate carbon carbon bonds and precisely set stereocentersIf chemists were to collaborate with the enzymes in these assembly linessyntheses of compounds in the drug discovery process would be greatly accelerated and ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Improving Patient Outcomes through Tracking and Displaying the Disinfection Status of Equipment and Area

    SBC: XENEX DISINFECTION SERVICES INC.            Topic: 600

    Inhealthcare associated infectionsHAIswere reported in the United StatesDaily and terminal disinfection of hospital areas such as patient rooms are critically important to help prevent HAI and involve extensive disinfection of the room before a new patient is admitted to the roomAdditionallyportable medical equipmentPMEhas been implicated in outbreaks of HAIs and the importance of systematic disin ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Numeric Expansion of CD-19 Specific T cells in Magnetic 3D Culture

    SBC: CHEMOSEN3D INC            Topic: NIAID

    Project Summary Adoptive immunotherapy trials using genetically modified natural killerNKand T cells with redirected specificity against B cell malignancies have demonstrated therapeutic efficacyTwo early phase clinical trials have been initiated at The University of Texas MDAnderson Cancer Center to evaluate the safety and efficacy of adoptive transfer of autologous and allogeneic T cells express ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Small molecule Inhibitors of steroid receptor coactivator to treat breast cancer

    SBC: Coactigon, Inc.            Topic: 102

    ABSTRACTSteroid Receptor CoactivatorSRCis a key breast cancer oncogene that is frequently overexpressed or amplified in estrogen receptorERand human epidermal growth factor receptorHERpositive breast cancersElevated expression of SRCalso has been associated with resistance to tamoxifen therapy and with poor disease outcome in HERpositive breast cancersNumerous studies have shown that experimental ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government